Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab and Cemiplimab in Early-stage, Resectable NSCLC
NCT06088771Phase 2Recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dupilumab and cemiplimab in non-small cell lung cancer (NSCLC), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoints: Frequency of dose limiting toxicities at 30 days, Percentage of dose limiting toxicities at 30 days and 1 more. Started Oct 2024; status: recruiting.
02
Drugs
dupilumabcemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06088771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06088771.